




# Ischemic Stroke Secondary to Large Vessel Occlusion: Where are We Today?

**Donald Frei, M.D.**

*Director, Neuro-interventional Surgery*

Swedish Medical Center




# Disclosures




- Consultant/speakers bureau
  - Genentech, Penumbra, Stryker
- Research support
  - Cerenovus, Medtronic, Microvention, Penumbra, Stryker
- Stock ownership
  - Penumbra

# Objectives



- The problem
- The options
- The evidence
- The solution
- The challenges

# The Problem



*Stroke: The sudden death of brain cells due to lack of oxygen, caused by blockage of blood flow or rupture of an artery to the brain.*


# Stroke

**Hemorrhagic:**  
**13%**

**Ischemic:**  
**87%**


Stroke  
Etiology

## Ischemic stroke causes



# Ischemic Stroke

- Stroke affects >800,000 people in US each year
- It is the 4<sup>th</sup> leading cause of death in North America
  - >150,000 deaths in US/year
- Morbidity
  - 15-30% permanently disabled
- Economic
  - 2012 direct and indirect cost of stroke: \$45.5 billion



<https://www.cdc.gov/stroke/>

# Time is Brain

 Neurons Lost	Synapses Lost	Accelerated Aging	
Per Stroke	1.2 billion	8.3 trillion	36 yrs
Per Hour	120 million	830 billion	3.6 yrs
Per Minute	1.9 million	14 billion	3.1 weeks
Per Second	32,000	230 million	8.7 hrs

(Total number of neurons in the average human brain is 130 billion)


# LVO Background - USA

**Table 5: J.P. Morgan US Stroke Market Model**

	2014	2015E	2016E	2017E	2018E	2019E	2020E
US Stroke Patients	795,000	818,850	843,416	868,718	894,780	921,623	949,272
% Ischemic	87%	87%	87%	87%	87%	87%	87%
US Ischemic Stroke Patients	691,650	712,400	733,771	755,785	778,458	801,812	825,866
% Large Vessel Strokes	43%	43%	43%	43%	43%	43%	43%
US Large Vessel Strokes	297,410	306,332	315,522	324,987	334,737	344,779	355,122
% Treatable with Salvageable Tissue	50%	50%	50%	50%	50%	50%	50%
US Ischemic Stroke Patients with ELVO	148,705	153,166	157,761	162,494	167,369	172,390	177,561
% of US Ischemic ELVO Patients Treated	7.9%	11.5%	13.8%	17.3%	21.0%	25.0%	28.5%
<b>US Ischemic ELVO Patients Treated</b>	<b>11,750</b>	<b>17,616</b>	<b>21,695</b>	<b>28,033</b>	<b>35,150</b>	<b>43,100</b>	<b>50,608</b>

**Thrombectomy - 100% increase, 2014 -> 2016, but  
We only treated < 20% of eligible patients in 2016**

# Mismatch: Penumbra



MRI/CT Abnormality: Bioenergetic Compromise = Core




Perfusion Abnormality: Hemodynamic Compromise = Ischemic



Diffusion/Perfusion Mismatch = Penumbra


# Why is Time Important?

- The area peripheral to a core infarct where metabolism is active but blood flow is diminished is called the **ischemic penumbra**
  - This is salvageable tissue that is at risk for infarction.
- The penumbra lies in a 'no-man's land' between a zone of low blood flow that is  $< 25$  ml/100 mg brain tissue/min and a zone where brain tissue is undergoing necrosis/death, flow of  $< 8-10$  ml/100 mg/min<sup>1</sup>
- Without restoration of blood flow/oxygen, the ischemic penumbra will convert to ischemic core or tissue death



1- <http://medical-dictionary.thefreedictionary.com/ischemic-penumbra>

# The Options



- Medical supportive care
- Intravenous t-PA
  - Clot busting medicine
  - < 3 hours from symptom onset
- Thrombectomy
  - Endovascular clot removal
  - Appropriate for LVO (large vessel occlusion)
  - < 24 hours from symptom onset based upon advanced imaging based patient selection

# Intravenous Recombinant Tissue Plasminogen Activator

## The New England Journal of Medicine

©Copyright, 1995, by the Massachusetts Medical Society

Volume 333

DECEMBER 14, 1995

Number 24

**TISSUE PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE**

THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE t-PA STROKE STUDY GROUP\*

- 333 patients, Published December 1995.
- Compared with patients given placebo vs. patients treated with t-PA **within 3 hours**
- Patients treated with t-PA were at least **30 percent more likely** to have minimal or no disability at three months.

# Options for Patients Experiencing an Ischemic Stroke



# Thrombectomy Goals

Normal






Occlusive clot

Thrombectomy



Normal



# TICI Score

Thrombolysis in Cerebral Infarction Score

TICI 0



**No perfusion**

TICI 1




**Limited Perfusion**

TICI 2a




**< 50% vascular  
territory**

TICI 2b



**≥ 50% vascular  
territory**


TICI 3



**Full Perfusion**


Mokin et al; Neurosurg Focus 2014

# Reperfusion with IV rt-PA




# Endovascular Clot Removal

Endovascular clot removal is a type of minimally invasive surgery that allows the physician to access various parts of the body, including the brain, through the body's major blood vessels.



# Goal of Ischemic Stroke Treatment

**To open the blocked blood vessel, thereby restoring oxygen and nutrients to the affected territories in the brain**



**Before Intervention**  
The blood vessels in the circle are not visible because a blood clot is blocking blood flow to those vessels.



**After Successful Intervention**  
Once the blood clot is removed, the blood vessels fill with blood and are visible again.

# Buying Time: Assessing collateral status

ORIGINAL RESEARCH

Journal of


NEUROINTERVENTIONAL SURGERY

## CT perfusion-guided patient selection for endovascular recanalization in acute ischemic stroke: a multicenter study

Aquilla S Turk,<sup>1</sup> Jordan Asher Magarick,<sup>2</sup> Don Frei,<sup>3</sup> Kyle Michael Fargen,<sup>4</sup> Imran Chaudry,<sup>1</sup> Christine A Holmstedt,<sup>2</sup> Joyce Nicholas,<sup>2</sup> J Mocco,<sup>5</sup> Raymond D Turner,<sup>2</sup> Daniel Huddle,<sup>3</sup> David Loy,<sup>3</sup> Richard Bellon,<sup>3</sup> Gwendolyn Dooley,<sup>3</sup> Robert Adams,<sup>2</sup> Michelle Whaley,<sup>3</sup> Chris Fanale,<sup>3</sup> Edward Jauch<sup>2</sup>


- Three medical centers retrospectively assessed stroke patients with a NIHSS of  $\geq 8$ , regardless of time from symptom onset, who had CT perfusion maps that defined salvageable penumbra and underwent intra-arterial revascularization.
- Patients were divided into two groups for analysis:  $\leq 8$  h and  $> 8$  h from symptom onset to endovascular procedure.

# CT Perfusion: Completed Infarct




# CT Perfusion: Salvageable Penumbra


CBV





CBF





MTT







# Thrombectomy Devices



**MERCI Retriever**





**Aspiration**



**Stentriever**



# Rapid Evolution of Thrombectomy Approaches



# Improvements in Technology


Arrival of stentriever and larger/more navigable aspiration catheters

- Easier to use
- More predictable outcomes
- Faster vessel recanalization




# Stroke Case: Pre-Procedure

32 year old smoker,  
hypertension. Prior episodes of  
slurred speech but never  
sought medical attention.  
Witnessed onset of aphasia,  
Right hemiplegia and left gaze  
preference. Pre treatment  
NIHSS=20. IV tPA given




# Stroke Case: Imaging




CT Scan RAPID analysis demonstrates a small area of infarct and a large area of hypoperfusion. There is also an old stroke on the contralateral (right) side.

# Stroke Case: Angiography



Initial angiography confirms large vessel occlusion (left M1 segment)

# Stroke Case




ADAPT direct aspiration technique. Puncture to recanalization 14 minutes.  
Repeat angiography demonstrates complete recanalization


# 5 Min Post-Procedure




Puncture to  
recanalization: 14mins.  
24 hour NIHSS=1




# 24h Post-Procedure



90 day follow up neurologically  
intact; mRS=0



# The Evidence



- IV t-PA has been approved for treatment of acute ischemic stroke since 1996.
- It has to be administered within 3 hours of symptom onset
  - Up to 4.5 hours based upon recent European trials
- Evidence for endovascular treatment
  - 2015
  - 2018

# New England Journal of Medicine 2015: Clear and Convincing Data

- Since January 1<sup>st</sup> of 2015, FIVE major prospective, randomized controlled trials have been published **comparing mechanical thrombectomy to best medical management:**
  - MR CLEAN
  - ESCAPE
  - EXTEND-IA
  - SWIFT PRIME
  - REVASCAT

# A Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN)

*The* **NEW ENGLAND**  
**JOURNAL** *of* **MEDICINE**

ESTABLISHED IN 1812

JANUARY 1, 2015

VOL. 372 NO. 1

## A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke

O.A. Berkhemer, P.S.S. Fransen, D. Beumer, L.A. van den Berg, H.F. Lingsma, A.J. Yoo, W.J. Schonewille, J.A. Vos, P.J. Nederkoorn, M.J.H. Wermer, M.A.A. van Walderveen, J. Staals, J. Hofmeijer, J.A. van Oostayen, G.J. Lycklama à Nijeholt, J. Boiten, P.A. Brouwer, B.J. Emmer, S.F. de Bruijn, L.C. van Dijk, L.J. Kappelle, R.H. Lo, E.J. van Dijk, J. de Vries, P.L.M. de Kort, W.J.J. van Rooij, J.S.P. van den Berg, B.A.A.M. van Hasselt, L.A.M. Aerden, R.J. Dallinga, M.C. Visser, J.C.J. Bot, P.C. Vroomen, O. Eshghi, T.H.C.M.L. Schreuder, R.J.J. Heijboer, K. Keizer, A.V. Tielbeek, H.M. den Hertog, D.G. Gerrits, R.M. van den Berg-Vos, G.B. Karas, E.W. Steyerberg, H.Z. Flach, H.A. Marquering, M.E.S. Sprengers, S.F.M. Jenniskens, L.F.M. Beenen, R. van den Berg, P.J. Koudstaal, W.H. van Zwam, Y.B.W.E.M. Roos, A. van der Lugt, R.J. van Oostenbrugge, C.B.L.M. Majoie, and D.W.J. Dippel, for the MR CLEAN Investigators\*

- Sites: 16 centers in Netherlands
- Patients: 500
  - 233 randomized to IA thrombectomy
  - 267 randomized to medical management
- Age 18+
- Included mild-severe stroke severity
- Time: Treatment initiated within 6 hrs
- Primary Outcome: mRS at 90 days
- Treatment in IA arm: No requirement, but retrievable stent in majority

Berkhemer et al; *NEJM*, 2015

# A Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN)


**Good Outcome (mRS 0-2):**

**33%** in IA thrombectomy group

**19%** in medical group

**Conclusion:**

Significantly better outcomes with thrombectomy compared to medical management



**Table 2. Primary and Secondary Outcomes and Treatment Effects.\***

Outcome	Intervention (N=233)	Control (N=267)	Effect Variable	Unadjusted Value (95% CI)	Adjusted Value (95% CI)†
Primary outcome: modified Rankin scale score at 90 days — median (interquartile range)	3 (2 to 5)	4 (3 to 5)	Common odds ratio	1.66 (1.21 to 2.28)	1.67 (1.21 to 2.30)
Secondary outcomes					
Clinical outcomes					
Modified Rankin score of 0 or 1 at 90 days — no. (%)	27 (11.6)	16 (6.0)	Odds ratio	2.06 (1.08 to 3.92)	2.07 (1.07 to 4.02)
Modified Rankin score of 0–2 at 90 days — no. (%)	76 (32.6)	51 (19.1)	Odds ratio	2.05 (1.36 to 3.09)	2.16 (1.39 to 3.38)

# Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE)

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


## Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke

M. Goyal, A.M. Demchuk, B.K. Menon, M. Eesa, J.L. Rempel, J. Thornton, D. Roy, T.G. Jovin, R.A. Willinsky, B.L. Sapkota, D. Dowlatshahi, D.F. Frei, N.R. Kamal, W.J. Montanera, A.Y. Poppe, K.J. Ryckborst, F.L. Silver, A. Shuaib, D. Tampieri, D. Williams, O.Y. Bang, B.W. Baxter, P.A. Burns, H. Choe, J.-H. Heo, C.A. Holmstedt, B. Jankowitz, M. Kelly, G. Linares, J.L. Mandzia, J. Shankar, S.-I. Sohn, R.H. Swartz, P.A. Barber, S.B. Coutts, E.E. Smith, W.F. Morrish, A. Weill, S. Subramaniam, A.P. Mitha, J.H. Wong, M.W. Lowerison, T.T. Sajobi, and M.D. Hill for the ESCAPE Trial Investigators\*

- Sites: 22 centers mostly in N America
- Patients: 315 (halted early due to efficacy)
  - 165 randomized to IA thrombectomy
  - 150 randomized to medical
- Age 18+
- Included mild-severe strokes
- Time: Treatment within 12 hours of onset
- Primary Outcome: mRS at 90 days
- Treatment in IA arm: Retrievable stent

Goyal et al; *NEJM*, 2015

# Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE)



**Good Outcome (mRS 0-2):**  
**53%** in IA thrombectomy group  
**29%** in medical group

**Conclusion:**  
 Significantly better outcomes with thrombectomy compared to medical management

**Table 2. Primary and Secondary Efficacy Outcomes.**

Outcome	Intervention (N=165)	Control (N=150)	Difference (95% CI)*	Effect Variable	Unadjusted Value (95% CI)	Adjusted Value (95% CI)†
Primary outcome: modified Rankin score at 90 days‡				Common odds ratio	2.6 (1.7–3.8)	3.1 (2.0–4.7)
Modified Rankin score of 0–2 at 90 days — no./total no. (%)§	87/164 (53.0)	43/147 (29.3)	23.8 (13.2–34.4)	Rate ratio	1.8 (1.4–2.4)	1.7 (1.3–2.2)

# Extending the Time for Thrombolysis in Emergency Neurological Deficits – Intra-Arterial (EXTEND-IA)

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


## Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection

B.C.V. Campbell, P.J. Mitchell, T.J. Kleinig, H.M. Dewey, L. Churilov, N. Yassi, B. Yan, R.J. Dowling, M.W. Parsons, T.J. Oxley, T.Y. Wu, M. Brooks, M.A. Simpson, F. Miteff, C.R. Levi, M. Krause, T.J. Harrington, K.C. Faulder, B.S. Steinfort, M. Priglinger, T. Ang, R. Scroop, P.A. Barber, B. McGuinness, T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.F. Bladin, M. Badve, H. Rice, L. de Villiers, H. Ma, P.M. Desmond, G.A. Donnan, and S.M. Davis, for the EXTEND-IA Investigators\*

- Sites: 10 centers mostly in Australia and New Zealand
- Patients: 70 (halted early due to efficacy)
  - 35 randomized to IA thrombectomy
  - 35 randomized to medical
- Age 18+
- Included mild-severe strokes
- Time: Within 6 hours of onset
- Primary Outcomes:
  1. Reperfusion at 24 hours (% reduction in perfusion-lesion volume)
  2. Decrease in NIHSS of 8 or more points at 3 days, or NIHSS of 0 or 1 at 3 days
- Treatment in IA arm: retrievable stent

Campbell et al; *NEJM*, 2015

# Extending the Time for Thrombolysis in Emergency Neurological Deficits – Intra-Arterial (EXTEND-IA)



**Good Outcome (mRS 0-2):**

**71%** in IA thrombectomy group

**40%** in medical group

**Conclusion:**

Significantly better outcomes with thrombectomy compared to medical management

Outcome	Alteplase-Only Group (N=35)	Endovascular-Therapy Group (N=35)	Effect Size (95% CI)†			
			Adjusted	P Value	Unadjusted	P Value
<b>Primary outcomes</b>						
Median reperfusion at 24 hr (IQR) — (%)‡	37 (-0.5 to 96)	100 (100 to 100)	4.7 (2.5 to 9.0)	<0.001	4.9 (2.5 to 9.5)	<0.001
Early neurologic improvement — no. (%)§	13 (37)	28 (80)	6.0 (2.0 to 18.0)	0.002	6.8 (2.3 to 20)	<0.001
<b>Secondary outcomes</b>						
Score on the modified Rankin scale at 90 days¶						
Median score (IQR) on ordinal analysis	3 (1 to 5)	1 (0 to 3)	2.0	0.02	2.1 (1.2 to 3.8)	0.006
Independent outcome — no. (%)	14 (40)	25 (71)	4.2 (1.4 to 12)	0.01	3.8 (1.4 to 10.0)	0.009
Excellent outcome — no. (%)	10 (29)	18 (51)	2.4 (0.87 to 6.6)	0.09	2.6 (1.0 to 7.1)	0.05

# Solitaire With the Intention For Thrombectomy as PRIMARY Endovascular treatment (SWIFT PRIME)

- Sites: 39 centers mostly in US and Europe
- Patients: 196 (halted early due to efficacy)
  - 98 randomized to IA thrombectomy
  - 98 randomized to medical
- Age 18-80
- Included moderate-severe strokes
- Time: Within 6 hours of onset and within 1.5 hours of imaging
- Primary Outcome: mRS at 90 days
- Treatment in IA arm: retrievable stent

*The* **NEW ENGLAND**  
**JOURNAL of MEDICINE**

ESTABLISHED IN 1812


JUNE 11, 2015

VOL. 372 NO. 24

Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone  
in Stroke

Jeffrey L. Saver, M.D., Mayank Goyal, M.D., Alain Bonafe, M.D., Hans-Christoph Diener, M.D., Ph.D., Elad I. Levy, M.D., Vitor M. Pereira, M.D., Gregory W. Albers, M.D., Christophe Cognard, M.D., David J. Cohen, M.D., Werner Hacke, M.D., Ph.D., Olav Jansen, M.D., Ph.D., Tudor G. Jovin, M.D., Heinrich P. Mattle, M.D., Raul G. Nogueira, M.D., Adnan H. Siddiqui, M.D., Ph.D., Dileep R. Yavagal, M.D., Blaise W. Baxter, M.D., Thomas G. Devlin, M.D., Ph.D., Demetrius K. Lopes, M.D., Vivek K. Reddy, M.D., Richard du Mesnil de Rochemont, M.D., Oliver C. Singer, M.D., and Reza Jahan, M.D., for the SWIFT PRIME Investigators\*

# Solitaire With the Intention For Thrombectomy as PRIMARY Endovascular treatment (SWIFT PRIME)



**Good Outcome (mRS 0-2):**  
**60%** in IA thrombectomy group  
**35%** in medical group

**Conclusion:**  
 Significantly better outcomes with thrombectomy compared to medical management

**Table 2. Primary and Secondary Outcomes.\***

Outcome	Intravenous t-PA Alone (N=98)	Stent Retriever plus Intravenous t-PA (N=98)	Risk Ratio (95% CI)	P Value
Primary outcome: score on modified Rankin scale at 90 days†				
No. of patients with data	93	98		<0.001
Median score	3	2		
Interquartile range	2-5	1-4		
Secondary outcomes				
Clinical efficacy outcome				
Functional independence at 90 days — no./total no. (%)‡	33/93 (35)	59/98 (60)	1.70 (1.23-2.33)	<0.001

# Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT)

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

## Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke

T.G. Jovin, A. Chamorro, E. Cobo, M.A. de Miquel, C.A. Molina, A. Rovira, L. San Román, J. Serena, S. Abilleira, M. Ribó, M. Millán, X. Urra, P. Cardona, E. López-Cancio, A. Tomasello, C. Castaño, J. Blasco, L. Aja, L. Dorado, H. Quesada, M. Rubiera, M. Hernández-Pérez, M. Goyal, A.M. Demchuk, R. von Kummer, M. Gallofré, and A. Dávalos, for the REVASCAT Trial Investigators\*

- Sites: 4 centers in Spain
- Patients: 206
  - 103 randomized to IA thrombectomy
  - 103 randomized to medical
- Age 18-85
- Included mild-severe strokes
- Time: Within 8 hours of onset
  
- Primary Outcome: mRS at 90 days
- Treatment in IA arm: retrievable stent

# Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT)




Good Outcome (mRS 0-2):  
**44%** in IA thrombectomy group  
**28%** in medical group

**Conclusion:**  
 Significantly better outcomes with thrombectomy compared to medical management

**Table 2. Primary and Secondary Clinical and Imaging Outcomes.\***

Outcome	Thrombectomy (N=103)	Control (N=103)	Effect Variable	Unadjusted Value (95% CI)	Adjusted Value (95% CI)
Primary outcome: score on modified Rankin scale at 90 days	NA	NA	Common odds ratio	1.7 (1.04 to 2.7)	1.7 (1.05 to 2.8)
Secondary outcome					
Score of 0 to 2 on modified Rankin scale at 90 days — no. (%)†	45 (43.7)	29 (28.2)	Odds ratio	2.0 (1.1 to 3.5)	2.1 (1.1 to 4.0)

# Endovascular Stroke Trials



# ESCAPE Outcomes

## MEDICAL TREATMENT (No endovascular treatment)



**29%**  
Positive  
Outcome

**52%**  
Disability

**19%**  
Death

## ENDOVASCULAR TREATMENT (With medical treatment)



**53%**  
Positive  
Outcome

**37%**  
Disability

**10%**  
Death

# THINK ABOUT IT

In order to have one additional stroke patient be independent at 90 days

MR CLEAN



ESCAPE



EXTEND-IA




SWIFT-PRIME




Primary PCI vs. Thrombolysis for STEMI: Prevention of MI/Stroke/Death



# DAWN




# DEFUSE 3



# Conclusions from DAWN and DEFUSE 3

Selection should be based on imaging, not time



# AHA/ASA Guideline

## 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke

### A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

*Reviewed for evidence-based integrity and endorsed by the American Association of Neurological Surgeons and Congress of Neurological Surgeons*

*Endorsed by the Society for Academic Emergency Medicine*

William J. Powers, MD, FAHA, Chair; Alejandro A. Rabinstein, MD, FAHA, Vice Chair;  
Teri Ackerson, BSN, RN; Opeolu M. Adeoye, MD, MS, FAHA;  
Nicholas C. Bambakidis, MD, FAHA; Kyra Becker, MD, FAHA; José Biller, MD, FAHA;  
Michael Brown, MD, MSc; Bart M. Demaerschalk, MD, MSc, FAHA; Brian Hoh, MD, FAHA;  
Edward C. Jauch, MD, MS, FAHA; Chelsea S. Kidwell, MD, FAHA;  
Thabele M. Leslie-Mazwi, MD; Bruce Ovbiagele, MD, MSc, MAS, MBA, FAHA;  
Phillip A. Scott, MD, MBA, FAHA; Kevin N. Sheth, MD, FAHA;  
Andrew M. Southerland, MD, MSc; Deborah V. Summers, MSN, RN, FAHA;  
David L. Tirschwell, MD, MSc, FAHA; on behalf of the American Heart Association Stroke Council

3.7. Mechanical Thrombectomy (Continued)	COR	LOE	New, Revised, or Unchanged
7. In selected patients with AIS within 6 to 16 hours of last known normal who have LVO in the anterior circulation and meet other DAWN or DEFUSE 3 eligibility criteria, mechanical thrombectomy is recommended.	I	A	New recommendation.
8. In selected patients with AIS within 6 to 24 hours of last known normal who have LVO in the anterior circulation and meet other DAWN eligibility criteria, mechanical thrombectomy is reasonable.	IIa	B-R	New recommendation.
<p>The DAWN trial used clinical imaging mismatch (a combination of NIHSS score and imaging findings on CTP or DW-MRI) as eligibility criteria to select patients with large anterior circulation vessel occlusion for treatment with mechanical thrombectomy between 6 and 24 hours from last known normal. This trial demonstrated an overall benefit in function outcome at 90 days in the treatment group (mRS score 0–2, 49% versus 13%; adjusted difference, 33%; 95% CI, 21–44; posterior probability of superiority &gt;0.999).<sup>100</sup> In DAWN, there were few strokes with witnessed onset (12%). The DEFUSE 3 trial used perfusion-core mismatch and maximum core size as imaging criteria to select patients with large anterior circulation occlusion 6 to 16 hours from last seen well for mechanical thrombectomy. This trial showed a benefit in functional outcome at 90 days in the treated group (mRS score 0–2, 44.6% versus 16.7%; RR, 2.67; 95% CI, 1.60–4.48; <math>P&lt;0.0001</math>).<sup>100</sup> Benefit was independently demonstrated for the subgroup of patients who met DAWN eligibility criteria and for the subgroup who did not. DAWN and DEFUSE 3 are the only RCTs showing benefit of mechanical thrombectomy &gt;6 hours from onset. Therefore, only the eligibility criteria from these trials should be used for patient selection. Although future RCTs may demonstrate that additional eligibility criteria can be used to select patients who benefit from mechanical thrombectomy, at this time, the DAWN and DEFUSE-3 eligibility should be strictly adhered to in clinical practice.</p>			See Table XXIII in online Data Supplement 1.

**9. The technical goal of the thrombectomy procedure should be reperfusion to a modified Thrombolysis in Cerebral Infarction (mTICI) 2b/3 angiographic result to maximize the probability of a good functional clinical outcome.**

**I**

**A**

Recommendation reworded for clarity from 2015 Endovascular.  
See Table LXXXIII in online Data Supplement 1 for original wording.

Mechanical thrombectomy aims to achieve reperfusion, not simply recanalization. A variety of reperfusion scores exist, but the mTICI score is the current assessment tool of choice, with proven value in predicting clinical outcomes.<sup>176,177</sup> All recent endovascular trials used the mTICI 2b/3 threshold for adequate reperfusion, with high rates achieved. In HERMES, 402 of 570 patients (71%) were successfully reperfused to mTICI 2b/3.<sup>172</sup> Earlier trials with less efficient devices showed lower recanalization rates, 1 factor in their inability to demonstrate benefit from the procedure (IMS III, 41%; MR RESCUE, 25%). The additional benefit of pursuing mTICI of 3 rather than 2b deserves further investigation.




**10. As with IV alteplase, reduced time from symptom onset to reperfusion with endovascular therapies is highly associated with better clinical outcomes. To ensure benefit, reperfusion to TICI grade 2b/3 should be achieved as early as possible within the therapeutic window.**

**I**

**B-R**

Recommendation revised from 2015 Endovascular.

# Timing is Critical



# Time is Brain Analysis with EVT

JAMA | **Original Investigation**



## Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis

Jeffrey L. Saver, MD; Mayank Goyal, MD; Aad van der Lugt, MD; Bijoy K. Menon, MD; Charles B. L. M. Majoie, MD; Diederik W. Dippel, MD; Bruce C. Campbell, MD, PhD; Raul G. Nogueira, MD; Andrew M. Demchuk, MD; Alejandro Tomasello, MD; Pere Cardona, MD; Thomas G. Devlin, MD; Donald F. Frei, MD; Richard du Mesnil de Rochemont, MD; Olvert A. Berkhemer, MD; Tudor G. Jovin, MD; Adnan H. Siddiqui, MD, PhD; Wim H. van Zwam, MD; Stephen M. Davis, MD; Carlos Castaño, MD; Biggya L. Sapkota, MD; Puck S. Fransen, MD; Carlos Molina, MD; Robert J. van Oostenbrugge, MD; Ángel Chamorro, MD; Hester Lingsma, PhD; Frank L. Silver, MD; Geoffrey A. Donnan, MD; Ashfaq Shuaib, MD; Scott Brown, PhD; Bruce Stouch, PhD; Peter J. Mitchell, MD; Antoni Davalos, MD; Yvo B. W. E. M. Roos, MD; Michael D. Hill, MD, MS; for the HERMES Collaborators



JAMA. 2016;316(12):1279-1288. doi:[10.1001/jama.2016.13647](https://doi.org/10.1001/jama.2016.13647)

# Process Efficiencies Matter after arrival at Endovascular Hospital

Figure 3. Relation Between In-Hospital Treatment Speeds and Functional Independence (mRS 0-2) at 3 Months Among Direct Arrival Patients in the Endovascular Thrombectomy Group Achieving Substantial Reperfusion (mTICI score, 2b or 3)



JAMA. 2016;316(12):1279-1288. doi:10.1001/jama.2016.13647



< 60 minutes

- Neurological evaluation
- Imaging evaluation
- Thrombectomy



The Medical Center of Aurora




GUNNISON VALLEY HEALTH



ASPEN VALLEY HOSPITAL



East Morgan County Hospital



PAGOSA SPRINGS Medical Center  
Better health and wellness where you live



# SWEDISH STROKE TEAM




# Swedish Medical Center

## Neurovascular Team


- 14 + hospitalist neurologists
  - Evaluate patients from 60 telemedicine hospitals in the western USA
  - Neurologist meets ALL stroke patients upon arrival
  - In suspected LVO patients, the INR team meets the patient upon arrival in CT - 24/7/365
- 4 neuro-interventional surgeons
- 6 stroke nurse practitioners

# COMPREHENSIVE STROKE CENTERS



SOURCE: American Heart Association

# Swedish Medical Center Spoke and Hub Treatment Area – 10 million population



© 2003 Encyclopædia Britannica, Inc.

# *Air Ambulance 2010 Program of the Year!*



*It's About The Experience!*


*Named #1 in the Country  
by the national Association of  
Air Medical Services (AAMS)*



*Since 1983*

# Sunday November 20, 2016



- 29 y.o. male transferred from Billings, Montana
- Marfans syndrome, intubated before transfer



2 hour fixed wing flight  
600 miles

# Sunday November 20, 2016

- 29 y.o. male transferred from Billings, Montana
- Marfans syndrome, intubated before transfer
- Door - 3:50 pm
- CT - 4:00 pm



# Sunday November 20, 2016

- 29 y.o. male transferred from Billings, Montana
- Marfans syndrome, intubated before transfer
- Door – 3:50 pm
- CT - 4:00 pm
- Access - 4:23 pm

4:23 pm



TICI 3 recanalization – 1 pass ACE 68



[AQ


# Sunday November 20, 2016



- 29 y.o. male transferred from Billings, Montana
- Marfans syndrome, intubated before transfer
- Door – 3:50 pm
- CT - 4:00 pm
- Access - 4:23 pm
- Recan. - 4:36 pm


**Door – recanalization  
46 minutes**

Friday night, 7:00 pm, at my home, with visiting physicians from Japan

- 31 y.o. female – aphasia, right hemiplegia
- Cardiomyopathy, ejection fraction 10%
- Not therapeutic on coumadin
- CT/CTA at a hospital 9 miles away at 6:42 pm
  - Reviewed prior to arrival










24 hour MRI, NIHSS - 1

90 mRS - 0



# LVO Stroke - Time is Brain

- 1.8 million neurons lost each minute
- Probability of a good outcome reduced 10% every 30 minutes until treated<sup>1</sup>
- Every 30 minute delay to revascularization = 7% increased risk of moderate to severe disability and 11.8% increase in mortality<sup>2</sup>




1. Stroke 2006; 37: 263–266

2. Linfante et al. Predictors of mortality in acute ischemic stroke intervention: analysis of the North American Solitaire Acute Stroke Registry. Stroke 2015;46;2305-8.

# Passage of time from the start of the stroke occurs differently for every patient


- Data supports a time window, but is the window the same for all patients?
  - **Wake up Stroke:** “last time known well” excludes many from treatment
  - **Posterior Strokes:** tolerate ischemia longer than anterior stroke and may have viable penumbra beyond 6 or 8 hours
  - **Collateral Circulation:** affects a patient’s ability to tolerate an occluded vessel
- An alternative to the traditional time window may be advanced imaging techniques in selected patients
  - CT Perfusion
  - MRI Diffusion/Perfusion

# Early Treatment = Better Outcome



Marler J.R. et. al., Early Stroke Treatment Associated with Better Outcome, The NINDS rt-PA Stroke Study Neurology 55 December 2000.

# The Solution



# LVO Stroke Treatment – A Team Sport

- Community Education
- EMS appropriate triage to IA capable facility
- Rapid ED evaluation and triage to endovascular
- Acute Neurology/Neurointerventional Surgery consultation
- t-PA and/or Embolectomy
- Neurocritical care
- Rehabilitation
- Risk factor modification

# Stroke Chain of Survival




- Detection: Early stroke recognition
- Dispatch: Early EMS activation
- Delivery: Transport, triage & management
- Door: ED triage
- Data: ED evaluation & management
- Decision: Neurology input, therapy selection
- Drug: Thrombolytics & Endovascular therapies
- Disposition: Admission or transfer

# Is it a stroke? Check these signs **FAST!**

## **F**ace



## **A**rm



## **S**peech




## **T**ime



Act **FAST**. Call 9-1-1 at any sign of stroke!

Massachusetts Department of Public Health

# Stroke scales mobile app



Stroke Scales  
for EMS

Select your stroke scale

LAMS

RACE

CPSSS

FAST-ED

VAN

- Tool for first responders to assess stroke severity in the field
- Based on results, app recommends the type of facility to which the stroke patient should be transported.

# Stroke scales mobile app

🏠 LAMS

1 2 3

Facial droop with smile?

No

Yes

🏠 LAMS

1 2 3

Lift both arms up in front of you.

No arm drift

Arm drifts down on one side

Arm falls rapidly on one side

🏠 LAMS

1 2 3

Grip strength?

Normal

Weak grip on one side

**Results: Likely a large vessel occlusive stroke.**

LAMS Score: 4 out of 4

Recommend endovascular capable stroke center.

 E-mail Results

 Text Results

Take Another LAMS Test

[Change My Scale](#)

# Thank You

[don.frei@riaco.com](mailto:don.frei@riaco.com)

